Cargando…
P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer
Current lung cancer treatment strategies are ineffective, and lung cancer cases continue to soar; thus, novel anticancer drugs and targets are needed, and medicinal plants are promising to offer better alternatives. This study was aimed at analysing two p53 splice variants during the potential antic...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235921/ https://www.ncbi.nlm.nih.gov/pubmed/35769912 http://dx.doi.org/10.3389/fmolb.2022.876213 |
_version_ | 1784736422203228160 |
---|---|
author | Laka, K. Mbita, Z. |
author_facet | Laka, K. Mbita, Z. |
author_sort | Laka, K. |
collection | PubMed |
description | Current lung cancer treatment strategies are ineffective, and lung cancer cases continue to soar; thus, novel anticancer drugs and targets are needed, and medicinal plants are promising to offer better alternatives. This study was aimed at analysing two p53 splice variants during the potential anticancer activities of Drimia calcarata (Dc) methanol and water extracts against different human lung cancer cell lines of varying p53 mutation status, and these included mutant H1573 and mutant H1437 and p53-wild type (A549) cells. The anticancer activities of the Dc extracts were assessed by establishing the cytotoxic effect and the apoptosis-inducing capacity of these extracts, using the MTT assay and Annexin V analysis, respectively, with the latter confirmed using fluorescence microscopy. The molecular mechanisms induced by these extracts were further evaluated using cell cycle analysis and RT-PCR. Both extracts demonstrated safety against noncancerous lung MRC-5 fibroblasts and exhibited significant anticancer potency (p < 0.001) against the H1437 (IC(50) values: 62.50 μg/ml methanol extract and 125 μg/ml WE), H1573 (IC(50) value: 125 μg/ml for both extracts) and A549 (IC(50) value: 500 μg/ml ME). The water extract had no effect on the viability of A549 cells. Treated H1437 cells underwent p53-dependent apoptosis and S-phase cell cycle arrest while H1573 treated cells underwent p53-independed apoptosis and G0/G1 cell cycle arrest through upregulation of p21 mRNA expression levels. The expression levels of STAT1, STAT3, STAT5A and STAT5B genes increased significantly (p < 0.001) following the treatment of H1573 cells with ME and WE. Treatment of H1437 cells with ME upregulated the STAT1, STAT3, STAT5A and STAT5B mRNAs. Our results indicate that the proliferative inhibitory effect of D. calcarata extracts on A549 and H1573 cells is correlated with the suppression of Bcl-2, STAT3 and STAT5B while that is not the case in H1437 cells. Thus, our results suggest that the dysregulation of anti-apoptotic molecules Bcl-2, STAT3, STAT5A and STAT5B in H1437 may play a role in cancer cell survival, which may consequently contribute to the development of p53-mutated non-small human lung cancer. Our results indicate that D. calcarata is a promising source of anticancer agents for the treatment of p53-mutant human non-small lung cancer cells than the p53-wild type human non-small lung cancer cells. |
format | Online Article Text |
id | pubmed-9235921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92359212022-06-28 P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer Laka, K. Mbita, Z. Front Mol Biosci Molecular Biosciences Current lung cancer treatment strategies are ineffective, and lung cancer cases continue to soar; thus, novel anticancer drugs and targets are needed, and medicinal plants are promising to offer better alternatives. This study was aimed at analysing two p53 splice variants during the potential anticancer activities of Drimia calcarata (Dc) methanol and water extracts against different human lung cancer cell lines of varying p53 mutation status, and these included mutant H1573 and mutant H1437 and p53-wild type (A549) cells. The anticancer activities of the Dc extracts were assessed by establishing the cytotoxic effect and the apoptosis-inducing capacity of these extracts, using the MTT assay and Annexin V analysis, respectively, with the latter confirmed using fluorescence microscopy. The molecular mechanisms induced by these extracts were further evaluated using cell cycle analysis and RT-PCR. Both extracts demonstrated safety against noncancerous lung MRC-5 fibroblasts and exhibited significant anticancer potency (p < 0.001) against the H1437 (IC(50) values: 62.50 μg/ml methanol extract and 125 μg/ml WE), H1573 (IC(50) value: 125 μg/ml for both extracts) and A549 (IC(50) value: 500 μg/ml ME). The water extract had no effect on the viability of A549 cells. Treated H1437 cells underwent p53-dependent apoptosis and S-phase cell cycle arrest while H1573 treated cells underwent p53-independed apoptosis and G0/G1 cell cycle arrest through upregulation of p21 mRNA expression levels. The expression levels of STAT1, STAT3, STAT5A and STAT5B genes increased significantly (p < 0.001) following the treatment of H1573 cells with ME and WE. Treatment of H1437 cells with ME upregulated the STAT1, STAT3, STAT5A and STAT5B mRNAs. Our results indicate that the proliferative inhibitory effect of D. calcarata extracts on A549 and H1573 cells is correlated with the suppression of Bcl-2, STAT3 and STAT5B while that is not the case in H1437 cells. Thus, our results suggest that the dysregulation of anti-apoptotic molecules Bcl-2, STAT3, STAT5A and STAT5B in H1437 may play a role in cancer cell survival, which may consequently contribute to the development of p53-mutated non-small human lung cancer. Our results indicate that D. calcarata is a promising source of anticancer agents for the treatment of p53-mutant human non-small lung cancer cells than the p53-wild type human non-small lung cancer cells. Frontiers Media S.A. 2022-06-13 /pmc/articles/PMC9235921/ /pubmed/35769912 http://dx.doi.org/10.3389/fmolb.2022.876213 Text en Copyright © 2022 Laka and Mbita. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Laka, K. Mbita, Z. P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer |
title |
P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer |
title_full |
P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer |
title_fullStr |
P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer |
title_full_unstemmed |
P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer |
title_short |
P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer |
title_sort | p53-related anticancer activities of drimia calcarata bulb extracts against lung cancer |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235921/ https://www.ncbi.nlm.nih.gov/pubmed/35769912 http://dx.doi.org/10.3389/fmolb.2022.876213 |
work_keys_str_mv | AT lakak p53relatedanticanceractivitiesofdrimiacalcaratabulbextractsagainstlungcancer AT mbitaz p53relatedanticanceractivitiesofdrimiacalcaratabulbextractsagainstlungcancer |